Points clés de l’étude

Points clés de l’étude1

INTI=inhibiteur nucléosidique de la transcriptase inverse; FDA = Food and Drug Administration; ARN = acide ribonucléique.
*+ 2 INTI au choix de l’investigateur : ténofovir 300 mg+ emtricitabine 200 mg OU abacavir 600 mg + lamivudine 300 mg.

Bibliographie:

  1. Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211-e220.
  2. Supplement to: Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211-e220.

DZ-DOR-00009. Date d’expiration: 1-10-2026